Treatment guidelines for chronic inflammatory demyelinating polyneuropathy (CIDP), an autoimmune neuro-muscular condition impacting the myelin that insulates and protects peripheral nerves causing mobility and sensory impairment, have been in place for many years with new treatment approvals being scarce. Newly …
Biomarker or molecular testing to help oncologists match patients with the best cancer treatment can be challenging in the community oncology setting and for patients in underserved communities. At present, patients with cancer in racially or ethnically underserved communities are …
Primary biliary cholangitis (PBC) is a chronic autoimmune disease of the intrahepatic bile ducts that is often misdiagnosed until it progresses to advanced stages, including end-stage liver disease. Symptoms such as intractable pruritus and severe fatigue, often accompanied by abnormal …
Unmet needs persist for patients with migraine, particularly for women and those in marginalized communities or who present to emergency care settings. To address these disparities, diagnosis and implementation of appropriate pharmacotherapy while factoring in social drivers of health and …
Ulcerative colitis (UC) affects around three million people in the United States. Delays in treatment coverage approval, costs of managing the disease, and uncertainties around new treatment options significantly impact how well patients react to treatment, and short- and long-term …
Despite the associated high probability of fetal risks in pregnant patients, mycophenolate remains one of the most commonly used immunosuppressants for patients receiving a solid organ transplant (SOT). To help combat the risks associated with mycophenolate treatment, the ongoing FDA …
The 2022 Clinical Practice Guideline for Prescribing Opioids for Pain, developed by the Centers for Disease Control and Prevention (CDC), was introduced as an update to the 2016 CDC Guideline for Prescribing Opioids for Chronic Pain. This update aimed to …
Despite advances in immunosuppressive therapy that have greatly extended survival for kidney graft recipients, challenges related to long-term implementation remain. Use of immunosuppressants is limited by their narrow therapeutic index, large intra- and inter-individual variability in pharmacokinetics, and drug-related toxicity, …
Effective shared decision-making (SDM) and addressing social drivers of health (SDoH) are critical for improving patient outcomes and reducing health care disparities. Low health literacy and inadequate patient-provider communication can lead to poor health outcomes, increased hospitalizations, and higher health …